Loading
NASDAQHealthcareMedical - Specialties
Latest quote
$4.02
−$0.13 · -3.13%
iTonic Holdings Ltd., a healthcare solutions firm, specializes in the development and commercialization of software and devices for brachytherapy. Its advanced proprietary treatment planning system centers on radioactive particle implantation, a form of radiotherapy employed in cancer treatment to precisely position radioactive sources within patients, thereby eradicating malignant cells and reducing tumor size. Key among its offerings is FTTPS, a sophisticated treatment planning system engineered for diverse malignant tumors. This system excels at defining the target volume, determining the prescribed dose, establishing safety margins for organs at risk, and formulating a precise dose distribution plan essential for brachytherapy patients. Founded in Beijing, China, in 1998, the company operated as Pheton Holdings Ltd. until its rebranding to iTonic Holdings Ltd. in January 2026. iTonic Holdings Ltd. functions as a subsidiary of ZJW (BVI) LTD.
Latest quote
$4.02
−$0.13 · -3.13%
After-hours
$4.02
$0.00 · 0.00%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
iTonic Holdings Ltd., a healthcare solutions firm, specializes in the development and commercialization of software and devices for brachytherapy. Its advanced proprietary treatment planning system centers on radioactive particle implantation, a form of radiotherapy employed in cancer treatment to precisely position radioactive sources within patients, thereby eradicating malignant cells and reducing tumor size. Key among its offerings is FTTPS, a sophisticated treatment planning system engineered for diverse malignant tumors. This system excels at defining the target volume, determining the prescribed dose, establishing safety margins for organs at risk, and formulating a precise dose distribution plan essential for brachytherapy patients. Founded in Beijing, China, in 1998, the company operated as Pheton Holdings Ltd. until its rebranding to iTonic Holdings Ltd. in January 2026. iTonic Holdings Ltd. functions as a subsidiary of ZJW (BVI) LTD.
Day range
Current $4.02
52-week range
Current $4.02
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
47
Fair Value
Sentiment
54
Mixed
Risk
87
Extreme Risk
Momentum
26
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
iTonic Holdings Ltd., a healthcare solutions firm, specializes in the development and commercialization of software and devices for brachytherapy. Its advanced proprietary treatment planning system centers on radioactive particle implantation, a form of radiotherapy employed in cancer treatment to precisely position radioactive sources within patients, thereby eradicating malignant cells and reducing tumor size. Key among its offerings is FTTPS, a sophisticated treatment planning system engineered for diverse malignant tumors. This system excels at defining the target volume, determining the prescribed dose, establishing safety margins for organs at risk, and formulating a precise dose distribution plan essential for brachytherapy patients. Founded in Beijing, China, in 1998, the company operated as Pheton Holdings Ltd. until its rebranding to iTonic Holdings Ltd. in January 2026. iTonic Holdings Ltd. functions as a subsidiary of ZJW (BVI) LTD.
Day range
Current $4.02
52-week range
Current $4.02
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 523.03K USD | 448.2K USD | 628.59K USD | 679.78K USD | 702.78K USD |
| Cost of goods sold | 195.68K USD | 103.26K USD | 157.76K USD | 121.63K USD | 112.03K USD |
| Gross profit | 327.35K USD | 344.94K USD | 470.83K USD | 558.15K USD | 590.74K USD |
| Research and development | 459.14K USD | 93.32K USD | 84.47K USD | 73.72K USD | 81.22K USD |
| Selling, general, and administrative | 5.06M USD | 1.02M USD | 693.03K USD | 456.91K USD | 371.44K USD |
| Operating expenses | 5.51M USD | 1.12M USD | 777.51K USD | 530.63K USD | 452.66K USD |
| Depreciation and amortization | 13.31K USD | 72.43K USD | 63.13K USD | 54.08K USD | 65.95K USD |
| Operating income | −5.19M USD | −770.27K USD | −306.68K USD | 27.52K USD | 138.09K USD |
| Net income | −5.1M USD | −660.59K USD | −241.22K USD | 83.98K USD | 192.46K USD |
Company facts updated Oct 8, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
